Article: AMDL's Jade Pharmaceutical Subsidiary Announces New Product Strategy; Six New Products, Including One With Sales Projected at Upwards of $10 Million, Under Development.

TUSTIN, Calif., Sept. 20 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI has a new product development strategy focusing on expanded in-house research and development activities and the in-licensing of new products from 3rd party pharmaceutical research firms.

Frank Zheng, Managing Director of JPI, stated "Our new product development ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!